Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES F LOVELL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1174629448
CMS profile
325880
Location
NORFOLK, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$4,516.90

64 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,705.48 10
Food and Beverage $1,811.42 54

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 64 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES F LOVELL

NPI 1174629448 · CMS profile ID 325880

Allopathic & Osteopathic Physicians / Internal Medicine

NORFOLK, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 64 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174629448?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 64 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174629448?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 64 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174629448?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 64 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1174629448?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

64 matching records · $4,516.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 64 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 64.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk AS $836.8112/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543313 CMS
Novo Nordisk AS $193.5512/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543315 CMS
Novo Nordisk AS $159.1112/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543317 CMS
Novo Nordisk AS $14.5012/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543319 CMS
Novo Nordisk AS $274.8312/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544629 CMS
Novo Nordisk AS $29.7512/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544631 CMS
ARBOR PHARMACEUTICALS, INC. $13.2212/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697363761 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.8011/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753384883 CMS
Novo Nordisk Inc $13.8610/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 690073957 CMS
Janssen Pharmaceuticals, Inc $79.1110/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658939461 CMS
Novartis Pharmaceuticals Corporation $17.5310/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659574319 CMS
ARBOR PHARMACEUTICALS, INC. $11.7009/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697363757 CMS
AstraZeneca Pharmaceuticals LP $24.8309/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685407031 CMS
SANOFI-AVENTIS U.S. LLC $20.3909/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694155873 CMS
Janssen Pharmaceuticals, Inc $2.5109/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658939457 CMS
Novo Nordisk AS $466.6009/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543153 CMS
Novo Nordisk AS $166.1409/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543155 CMS
Novo Nordisk AS $92.7109/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543157 CMS
Novo Nordisk AS $222.6209/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544565 CMS
Novartis Pharmaceuticals Corporation $18.2709/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659574317 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.8609/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753385673 CMS
LivaNova USA, Inc. $24.7009/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703467409 CMS
Amgen Inc. $20.8908/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662244203 CMS
Janssen Pharmaceuticals, Inc $2.5108/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658939453 CMS
Novo Nordisk Inc $11.0308/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674610519 CMS
Amgen Inc. $20.0508/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662244207 CMS
Merck Sharp & Dohme Corporation $10.9907/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695675179 CMS
PFIZER INC. $17.0707/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672360719 CMS
Novo Nordisk Inc $3.7407/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682744493 CMS
Novartis Pharmaceuticals Corporation $19.8807/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659574321 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.1607/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753384885 CMS
Janssen Pharmaceuticals, Inc $10.1707/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658939445 CMS
Janssen Pharmaceuticals, Inc $3.9706/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658939443 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $0.4106/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753384887 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $8.9506/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753384889 CMS
Radius Health, Inc. $27.2506/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683953537 CMS
Novo Nordisk Inc $11.4106/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674464105 CMS
Novo Nordisk Inc $38.5005/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 690073955 CMS
Novo Nordisk AS $311.0905/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543135 CMS
Novo Nordisk AS $224.8705/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543137 CMS
Novo Nordisk AS $240.1005/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543139 CMS
Novo Nordisk AS $350.0005/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544559 CMS
Novartis Pharmaceuticals Corporation $14.5005/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659574315 CMS
Novo Nordisk Inc $11.7905/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669566009 CMS
Amarin Pharma Inc. $21.1705/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699141161 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $4.4705/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753384891 CMS
Janssen Pharmaceuticals, Inc $10.6204/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658939435 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $99.1403/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700445695 CMS
Novartis Pharmaceuticals Corporation $21.0603/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659574311 CMS
Strongbridge US INC. $11.3703/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688229651 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,516.90 64
PY2020 $2,823.11 39
PY2021 $2,590.74 45
PY2022 $737.64 35
PY2023 $454.03 20
PY2024 $2,529.63 39
PY2025 $681.28 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $262,318.22 41
PY2024 Principal investigator $226,779.68 27
PY2023 Principal investigator $241,422.11 79
PY2022 Principal investigator $283,192.02 266
PY2021 Principal investigator $197,651.91 425
PY2020 Principal investigator $248,697.42 325
PY2019 Recipient $12,988.10 1
PY2019 Principal investigator $359,002.06 260

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

261 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $2,800.00 12/24/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
GOULD No dispute reported 06/30/2026 675778883
Principal investigator 1 Novo Nordisk AS $4,356.72 12/23/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692462603
Principal investigator 1 Novo Nordisk AS $885.38 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
NN9535-4321 No dispute reported 06/30/2026 692462607
Principal investigator 1 Novo Nordisk AS $15.80 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724409
Principal investigator 1 Novo Nordisk AS $29.98 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724411
Principal investigator 1 Novo Nordisk AS $10.40 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724413
Principal investigator 1 Novo Nordisk AS $55.54 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724415
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724417
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724419
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724421
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724423
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724425
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724427
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724429
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724431
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724433
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724435
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724437
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724439
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724441
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724443
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724445
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724447
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724449
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724451
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724453
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724455
Principal investigator 1 Novo Nordisk AS $34.14 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724457
Principal investigator 1 Novo Nordisk AS $25.96 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724459
Principal investigator 1 Novo Nordisk AS $18.30 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724461
Principal investigator 1 Novo Nordisk AS $72.00 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724463
Principal investigator 1 Novo Nordisk AS $7.32 12/19/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724465
Principal investigator 1 SANOFI US SERVICES INC. $927.35 12/11/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691597561
Principal investigator 1 Novo Nordisk AS $4,078.80 12/03/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
NN2211-4232 No dispute reported 06/30/2026 692462575
Principal investigator 1 Novo Nordisk AS $750.00 12/03/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
NN2211-4232 No dispute reported 06/30/2026 692462577
Principal investigator 1 Novo Nordisk AS $10,385.28 12/03/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692462601
Principal investigator 1 Novo Nordisk AS $3,946.52 12/03/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
NN9535-4321 No dispute reported 06/30/2026 692462605
Principal investigator 1 Novo Nordisk AS $24.99 11/21/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724531
Principal investigator 1 Akcea Therapeutics, Inc. $16,462.50 11/18/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
ISIS 678354-CS2 No dispute reported 06/30/2026 703181395
Principal investigator 1 Merck Sharp & Dohme Corporation $7,220.00 11/18/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691502499
Principal investigator 1 Novo Nordisk AS $24.99 11/15/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724533
Principal investigator 1 SANOFI US SERVICES INC. $900.00 11/13/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691599587
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724535
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724537
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724539
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724541
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724543
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724545
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724547
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724549
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724551
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724553
Principal investigator 1 Novo Nordisk AS $138.85 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724555
Principal investigator 1 Novo Nordisk AS $26.00 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724557
Principal investigator 1 Novo Nordisk AS $74.95 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724559
Principal investigator 1 Novo Nordisk AS $39.50 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724561
Principal investigator 1 Novo Nordisk AS $18.30 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724563
Principal investigator 1 Novo Nordisk AS $180.00 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724565
Principal investigator 1 Novo Nordisk AS $64.90 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724567
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724611
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724613
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724615
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724617
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724619
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724621
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724623
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724625
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724627
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724629
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724631
Principal investigator 1 Novo Nordisk AS $7.65 11/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724633
Principal investigator 1 SANOFI US SERVICES INC. $1,906.55 11/12/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691597837
Principal investigator 1 SANOFI US SERVICES INC. $262.65 11/12/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691597849
Principal investigator 1 Novo Nordisk AS $21.80 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724569
Principal investigator 1 Novo Nordisk AS $12.12 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724571
Principal investigator 1 Novo Nordisk AS $108.00 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724573
Principal investigator 1 Novo Nordisk AS $7.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724575
Principal investigator 1 Novo Nordisk AS $7.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724577
Principal investigator 1 Novo Nordisk AS $7.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724579
Principal investigator 1 Novo Nordisk AS $7.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724581
Principal investigator 1 Novo Nordisk AS $7.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724583
Principal investigator 1 Novo Nordisk AS $7.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724585
Principal investigator 1 Novo Nordisk AS $7.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724587
Principal investigator 1 Novo Nordisk AS $7.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724589
Principal investigator 1 Novo Nordisk AS $7.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724591
Principal investigator 1 Novo Nordisk AS $7.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724593
Principal investigator 1 Novo Nordisk AS $7.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724595
Principal investigator 1 Novo Nordisk AS $9.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724597
Principal investigator 1 Novo Nordisk AS $9.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724599
Principal investigator 1 Novo Nordisk AS $9.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724601
Principal investigator 1 Novo Nordisk AS $9.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724603
Principal investigator 1 Novo Nordisk AS $9.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724605
Principal investigator 1 Novo Nordisk AS $9.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724607
Principal investigator 1 Novo Nordisk AS $9.50 11/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724609
Principal investigator 1 Merck Sharp & Dohme Corporation $13.60 11/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691519739
Principal investigator 1 Merck Sharp & Dohme Corporation $1.40 11/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691532487
Principal investigator 1 Merck Sharp & Dohme Corporation $528.00 11/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691533805
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 11/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691533989
Principal investigator 1 Merck Sharp & Dohme Corporation $2.00 11/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691534355
Principal investigator 1 Merck Sharp & Dohme Corporation $55.00 11/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691534743
Principal investigator 1 Merck Sharp & Dohme Corporation $6.60 11/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691534745
Principal investigator 1 Merck Sharp & Dohme Corporation $67.20 11/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691534747
Principal investigator 1 Merck Sharp & Dohme Corporation $2.60 11/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691535283
Principal investigator 1 Merck Sharp & Dohme Corporation $242.00 11/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691535285
Principal investigator 1 Merck Sharp & Dohme Corporation $7.60 11/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691535621
Principal investigator 1 Kowa Research Institute, Inc. $1,752.00 11/07/2019 Non-covered Recipient Entity
York Clinical Research, LLC
K-877-303 No dispute reported 06/30/2026 629131307
Principal investigator 1 SANOFI US SERVICES INC. $6,548.10 11/04/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691596473
Principal investigator 1 Novo Nordisk AS $2,861.72 10/29/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
NN9535-4321 No dispute reported 06/30/2026 692462587
Principal investigator 1 Novo Nordisk AS $2,489.94 10/29/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692462589
Principal investigator 1 SANOFI US SERVICES INC. $4,055.35 10/28/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691594861
Principal investigator 1 Kowa Research Institute, Inc. $1,195.80 10/24/2019 Non-covered Recipient Entity
York Clinical Research, LLC
K-877-301 No dispute reported 06/30/2026 629123807
Principal investigator 1 SANOFI US SERVICES INC. $887.40 10/21/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691588797
Principal investigator 1 Merck Sharp & Dohme Corporation $10,505.00 10/11/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691483577
Principal investigator 1 Merck Sharp & Dohme Corporation $3.30 10/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691515737
Principal investigator 1 Merck Sharp & Dohme Corporation $6.80 10/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691518331
Principal investigator 1 Merck Sharp & Dohme Corporation $0.70 10/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691532471
Principal investigator 1 Merck Sharp & Dohme Corporation $1.00 10/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691532477
Principal investigator 1 Merck Sharp & Dohme Corporation $1.30 10/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691532481
Principal investigator 1 Merck Sharp & Dohme Corporation $33.60 10/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691533603
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 10/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691533803
Principal investigator 1 Merck Sharp & Dohme Corporation $121.00 10/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691533987
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 10/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691535287
Principal investigator 1 Merck Sharp & Dohme Corporation $27.50 10/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691535289
Principal investigator 1 Merck Sharp & Dohme Corporation $3.80 10/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691535471
Principal investigator 1 Merck Sharp & Dohme Corporation $7.10 10/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691535619
Principal investigator 1 Merck Sharp & Dohme Corporation $9.50 10/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691535623
Principal investigator 1 Novo Nordisk AS $49.98 10/04/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724529
Principal investigator 1 Novo Nordisk AS $10.20 09/30/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724527
Principal investigator 1 Novo Nordisk AS $24.99 09/27/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724525
Principal investigator 1 Novo Nordisk AS $3,000.00 09/26/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
NN9535-4416 No dispute reported 06/30/2026 692462569
Principal investigator 1 Novo Nordisk AS $2,497.50 09/26/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692462595
Principal investigator 1 Novo Nordisk AS $5,136.46 09/26/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
NN9535-4321 No dispute reported 06/30/2026 692462599
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $34.98 09/24/2019 Non-covered Recipient Entity
YORK CLINICAL RSRCH LLC NORFOLK
Exercise capacity study in HFpEF No dispute reported 06/30/2026 703550555
Principal investigator 1 Novo Nordisk AS $24.99 09/20/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724523
Principal investigator 1 Novo Nordisk AS $5.30 09/06/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724509
Principal investigator 1 Novo Nordisk AS $49.98 09/06/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724511
Principal investigator 1 Novo Nordisk AS $9.00 09/06/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724513
Principal investigator 1 Novo Nordisk AS $60.00 09/06/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724515
Principal investigator 1 Novo Nordisk AS $6.50 09/06/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724517
Principal investigator 1 Novo Nordisk AS $9.00 09/06/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724519
Principal investigator 1 Novo Nordisk AS $36.00 09/06/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724521
Principal investigator 1 Novo Nordisk AS $1,418.04 08/30/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692462593
Principal investigator 1 Novo Nordisk AS $2,500.00 08/30/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
NN9535-4321 No dispute reported 06/30/2026 692462597
Principal investigator 1 SANOFI US SERVICES INC. $1,388.05 08/28/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691590537
Principal investigator 1 Novo Nordisk AS $24.99 08/09/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724507
Principal investigator 1 Merck Sharp & Dohme Corporation $70.32 08/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691432349
Principal investigator 1 SANOFI US SERVICES INC. $2,037.45 08/07/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691584023
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $508.29 07/31/2019 Non-covered Recipient Entity
YORK CLINICAL RSRCH LLC NORFOLK
Exercise capacity study in HFpEF No dispute reported 06/30/2026 704735169
Principal investigator 1 Novo Nordisk AS $1,000.00 07/30/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
NN1250-4252 No dispute reported 06/30/2026 692462573
Principal investigator 1 Novo Nordisk AS $1,383.48 07/30/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692462591
Principal investigator 1 SANOFI US SERVICES INC. $2,144.55 07/25/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691581657
Principal investigator 1 SANOFI US SERVICES INC. $3,859.40 07/22/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691581677
Principal investigator 1 Merck Sharp & Dohme Corporation $11,875.00 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691419271
Principal investigator 1 Merck Sharp & Dohme Corporation $0.38 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691419277
Principal investigator 1 Merck Sharp & Dohme Corporation $0.68 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691419281
Principal investigator 1 Merck Sharp & Dohme Corporation $14.20 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691419445
Principal investigator 1 Merck Sharp & Dohme Corporation $17.00 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691419451
Principal investigator 1 Merck Sharp & Dohme Corporation $2.50 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691419453
Principal investigator 1 Merck Sharp & Dohme Corporation $2.75 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691419457
Principal investigator 1 Merck Sharp & Dohme Corporation $23.75 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691419459
Principal investigator 1 Merck Sharp & Dohme Corporation $3.25 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691419523
Principal investigator 1 Merck Sharp & Dohme Corporation $8.25 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691426583
Principal investigator 1 Merck Sharp & Dohme Corporation $84.00 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691426671
Principal investigator 1 Merck Sharp & Dohme Corporation $9.50 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691426787
Principal investigator 1 Merck Sharp & Dohme Corporation $302.50 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691428659
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691428663
Principal investigator 1 Merck Sharp & Dohme Corporation $660.00 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691428669
Principal investigator 1 Merck Sharp & Dohme Corporation $68.75 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691428673
Principal investigator 1 Merck Sharp & Dohme Corporation $1.75 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691431457
Principal investigator 1 Merck Sharp & Dohme Corporation $20.00 07/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691431545
Principal investigator 1 Novo Nordisk AS $40,128.81 07/02/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
NN1250-4252 No dispute reported 06/30/2026 692462571
Principal investigator 1 SANOFI US SERVICES INC. $1,865.30 07/02/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691581793
Principal investigator 1 Novo Nordisk AS $1.08 06/28/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724501
Principal investigator 1 Novo Nordisk AS $2.40 06/28/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724503
Principal investigator 1 Novo Nordisk AS $2.40 06/28/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724505
Principal investigator 1 Novo Nordisk AS $22.97 06/26/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724405
Principal investigator 1 Novo Nordisk AS $1,297.08 06/25/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692462585
Principal investigator 1 Merck Sharp & Dohme Corporation $6,485.00 06/14/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691356093
Principal investigator 1 Novo Nordisk AS $3.05 06/13/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724481
Principal investigator 1 Novo Nordisk AS $5.36 06/13/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724483
Principal investigator 1 Novo Nordisk AS $4.99 06/13/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724485
Principal investigator 1 Novo Nordisk AS $5.30 06/13/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724487
Principal investigator 1 Novo Nordisk AS $49.98 06/13/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724489
Principal investigator 1 Novo Nordisk AS $9.00 06/13/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724491
Principal investigator 1 Novo Nordisk AS $60.00 06/13/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724493
Principal investigator 1 Novo Nordisk AS $6.50 06/13/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724495
Principal investigator 1 Novo Nordisk AS $9.00 06/13/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724497
Principal investigator 1 Novo Nordisk AS $36.00 06/13/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 706724499
Principal investigator 1 Merck Sharp & Dohme Corporation $4.04 06/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372577
Principal investigator 1 Merck Sharp & Dohme Corporation $4.84 06/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372587
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 06/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691373063
Principal investigator 1 Merck Sharp & Dohme Corporation $1.20 06/10/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691374407
Principal investigator 1 SANOFI US SERVICES INC. $8,906.75 06/10/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691587163
Principal investigator 1 SANOFI US SERVICES INC. $3,984.80 06/10/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691587507
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $74.94 05/28/2019 Non-covered Recipient Entity
YORK CLINICAL RSRCH LLC NORFOLK
Exercise capacity study in HFpEF No dispute reported 06/30/2026 703550395
Principal investigator 1 Boehringer Ingelheim France S.A.S. $98.26 05/28/2019 Non-covered Recipient Entity
YORK CLINICAL RSRCH LLC NORFOLK
Exercise capacity study in HFrEF No dispute reported 06/30/2026 703550975
Principal investigator 1 Novo Nordisk AS $4,099.68 05/28/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692462583
Principal investigator 1 Merck Sharp & Dohme Corporation $3,295.00 05/22/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691324403
Principal investigator 1 Novo Nordisk AS $24.99 05/21/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724479
Principal investigator 1 Amgen Inc. $276.97 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH
GALACTIC-HF No dispute reported 06/30/2026 675797297
Principal investigator 1 Merck Sharp & Dohme Corporation $3.30 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372495
Principal investigator 1 Merck Sharp & Dohme Corporation $3.80 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372567
Principal investigator 1 Merck Sharp & Dohme Corporation $33.60 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372573
Principal investigator 1 Merck Sharp & Dohme Corporation $4.08 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372581
Principal investigator 1 Merck Sharp & Dohme Corporation $5.70 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372667
Principal investigator 1 Merck Sharp & Dohme Corporation $6.80 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372897
Principal investigator 1 Merck Sharp & Dohme Corporation $7.10 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372899
Principal investigator 1 Merck Sharp & Dohme Corporation $72.60 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372903
Principal investigator 1 Merck Sharp & Dohme Corporation $0.60 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691373059
Principal investigator 1 Merck Sharp & Dohme Corporation $14.20 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691373067
Principal investigator 1 Merck Sharp & Dohme Corporation $158.40 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691373125
Principal investigator 1 Merck Sharp & Dohme Corporation $16.50 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691373129
Principal investigator 1 Merck Sharp & Dohme Corporation $20.16 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691373133
Principal investigator 1 Merck Sharp & Dohme Corporation $247.50 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691373135
Principal investigator 1 Merck Sharp & Dohme Corporation $27.50 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691373141
Principal investigator 1 Merck Sharp & Dohme Corporation $0.70 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691374399
Principal investigator 1 Merck Sharp & Dohme Corporation $1.00 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691374401
Principal investigator 1 Merck Sharp & Dohme Corporation $1.30 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691374411
Principal investigator 1 Merck Sharp & Dohme Corporation $1.98 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691374415
Principal investigator 1 Merck Sharp & Dohme Corporation $0.42 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691374443
Principal investigator 1 Merck Sharp & Dohme Corporation $121.00 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691376153
Principal investigator 1 Merck Sharp & Dohme Corporation $2.28 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691376159
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691376229
Principal investigator 1 Merck Sharp & Dohme Corporation $0.78 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691376859
Principal investigator 1 Merck Sharp & Dohme Corporation $9.50 05/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691377047
Principal investigator 1 Boehringer Ingelheim France S.A.S. $151.40 04/25/2019 Non-covered Recipient Entity
YORK CLINICAL RSRCH LLC NORFOLK
Exercise capacity study in HFrEF No dispute reported 06/30/2026 703550973
Principal investigator 1 Novo Nordisk AS $1,223.04 04/25/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
NN1250-4252 No dispute reported 06/30/2026 692462567
Principal investigator 1 Novo Nordisk AS $648.54 04/25/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692462581
Principal investigator 1 SANOFI US SERVICES INC. $4,418.30 04/22/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691574765
Recipient SANOFI US SERVICES INC. $12,988.10 04/15/2019 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular No dispute reported 06/30/2026 691580971
Principal investigator 1 Merck Sharp & Dohme Corporation $13,305.00 04/12/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691326597
Principal investigator 1 Amgen Inc. $4,461.00 03/27/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
GALACTIC-HF No dispute reported 06/30/2026 675797303
Principal investigator 1 Novo Nordisk AS $2,239.92 03/26/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
EX9536-4388 No dispute reported 06/30/2026 692462609
Principal investigator 1 Merck Sharp & Dohme Corporation $8,290.00 03/15/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691324407
Principal investigator 1 Novo Nordisk AS $7.65 03/14/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724469
Principal investigator 1 Novo Nordisk AS $15.60 03/14/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724471
Principal investigator 1 Novo Nordisk AS $23.70 03/14/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724473
Principal investigator 1 Novo Nordisk AS $10.98 03/14/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724475
Principal investigator 1 Novo Nordisk AS $38.94 03/14/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724477
Principal investigator 1 Merck Sharp & Dohme Corporation $734.20 03/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691371787
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,595.66 03/06/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
Exercise capacity study in HFpEF No dispute reported 06/30/2026 704143845
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $711.60 02/28/2019 Non-covered Recipient Entity
YORK CLINICAL RSRCH LLC NORFOLK
Exercise capacity study in HFpEF No dispute reported 06/30/2026 704735207
Principal investigator 1 Novo Nordisk AS $10,000.00 02/26/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
NN9924-4221 No dispute reported 06/30/2026 692462579
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $36.50 02/25/2019 Non-covered Recipient Entity
YORK CLINICAL RSRCH LLC NORFOLK
Exercise capacity study in HFpEF No dispute reported 06/30/2026 703550327
Principal investigator 1 Boehringer Ingelheim France S.A.S. $47.00 02/25/2019 Non-covered Recipient Entity
YORK CLINICAL RSRCH LLC NORFOLK
Exercise capacity study in HFrEF No dispute reported 06/30/2026 703550883
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $843.98 02/25/2019 Non-covered Recipient Entity
YORK CLINICAL RSRCH LLC NORFOLK
MRD for BI 685509 in DN Patients No dispute reported 06/30/2026 704735137
Principal investigator 1 Novo Nordisk AS $1,303.20 02/21/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
NN1250-4252 No dispute reported 06/30/2026 692462565
Principal investigator 1 Kowa Research Institute, Inc. $1,047.60 02/14/2019 Non-covered Recipient Entity
York Clinical Research, LLC
K-877-301 No dispute reported 06/30/2026 629123805
Principal investigator 1 SANOFI US SERVICES INC. $5,681.40 02/11/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691563747
Principal investigator 1 Novo Nordisk AS $1.70 02/08/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 706724467
Principal investigator 1 Amgen Inc. $515.00 01/29/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH
GOULD No dispute reported 06/30/2026 675797301
Principal investigator 1 Amgen Inc. $19,487.00 01/29/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
GALACTIC-HF No dispute reported 06/30/2026 675797311
Principal investigator 1 Merck Sharp & Dohme Corporation $1,470.04 01/28/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691373121
Principal investigator 1 SANOFI US SERVICES INC. $2,869.60 01/28/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691562659
Principal investigator 1 SANOFI US SERVICES INC. $30,015.00 01/28/2019 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular No dispute reported 06/30/2026 691573739
Principal investigator 1 Amgen Inc. $7,700.00 01/26/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
GOULD No dispute reported 06/30/2026 675797315
Principal investigator 1 Merck Sharp & Dohme Corporation $10,108.00 01/24/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691311385
Principal investigator 1 Novo Nordisk AS $4,297.30 01/24/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
NN1250-4252 No dispute reported 06/30/2026 692462563
Principal investigator 1 Merck Sharp & Dohme Corporation $34.25 01/22/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691344323
Principal investigator 1 Novo Nordisk AS $75.00 01/16/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN1250-4252 No dispute reported 06/30/2026 706724407
Principal investigator 1 Amgen Inc. $7,731.74 01/01/2019 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
GALACTIC-HF No dispute reported 06/30/2026 675797307